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The serotonergic system and in particular serotonin 1A receptor (5-HT1AR) are implicated in
major depressive disorder (MDD). Here we demonstrated that 5-HT1AR is palmitoylated in
human and rodent brains, and identified ZDHHC21 as a major palmitoyl acyltransferase,
whose depletion reduced palmitoylation and consequently signaling functions of 5-HT1AR.
Two rodent models for depression-like behavior show reduced brain ZDHHC21 expression
and attenuated 5-HT1AR palmitoylation. Moreover, selective knock-down of ZDHHC21 in the
murine forebrain induced depression-like behavior. We also identified the microRNA miR-
30e as a negative regulator of Zdhhc21 expression. Through analysis of the post-mortem brain
samples in individuals with MDD that died by suicide we find that miR-30e expression is
increased, while ZDHHC21 expression, as well as palmitoylation of 5-HT1AR, are reduced
within the prefrontal cortex. Our study suggests that downregulation of 5-HT1AR palmi-
toylation is a mechanism involved in depression, making the restoration of 5-HT1AR palmi-
toylation a promising clinical strategy for the treatment of MDD.
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Major depressive disorder (MDD) is a prevalent mentalillness associated with mortality and secondary mor-bidity. MDD often leads to suicide, with approximately
800,000 people who die are due to suicide every year1. Dysre-
gulation of the serotonin system has long been considered central
to the etiology of MDD, and the main inhibitory serotonin
receptor 5-HT1A (5-HT1AR) seems to play a key role in
depressive neuropathology2,3 (Supplementary Fig. 1A). 5-HT1AR
is involved in the regulation of states of depression and anxiety4.
It has been shown that 5-HT1AR-deficient mice demonstrate
increased anxiety-related responses, fear conditioning, and
increased freezing behavior5. The overexpression of the 5-HT1AR
induced during the early postnatal period in the forebrain, but
not in the raphe nuclei, has been found to be sufficient to rescue
the behavioral phenotype of the knockout mice. These data
suggest an important role of postsynaptic 5-HT1AR in psychiatric
disorders6. It has been also demonstrated that decreased level of
5-HT1AR can lead to anxiety and stress disorders in mice and
primates7,8. Despite much effort, the molecular routes impairing
the serotonin system in clinical depression and suicide remain
largely enigmatic.
The 5-HT1AR couples to a variety of effectors via pertussis
toxin-sensitive heterotrimeric G proteins of the Gi/o family,
leading to the agonist-promoted adenylyl cyclase inhibition and a
subsequent decrease of the cAMP level9. In addition, G-protein
gated inwardly rectifying potassium (GIRK or Kir3) channels
constitute a central physiological downstream target of 5-HT1AR
in the brain (Supplementary Fig. 1A), and cultured neurons
produce a robust K+ current after 5-HT1AR stimulation via
GIRK channels10,11. Previously, we showed that 5-HT1AR is
palmitoylated at its C-terminal cysteine residues Cys417 and
Cys420 and that the mutation of palmitoylated cysteines reduces
Gi-protein receptor-mediated signaling via mis-localization of
receptor outside of the lipid rafts12,13. We also found that 5-
HT1AR palmitoylation efficiency was not modulated by the
receptor stimulation with agonists13.
In the present study, we found the palmitoylation of 5-HT1AR
to be specifically reduced within the prefrontal cortex (PFC) in
the postmortem samples from individuals with MDD who died
by suicide (DS). We also identified ZDHHC21 as the cognate
palmitoylating enzyme and found that reduced ZDHHC21
expression in the PFC of suicide subjects was connected to atte-
nuated 5-HT1AR palmitoylation status. These findings were
mirrored in several rodent models for depression-like behavior.
Searching for the mechanisms tuning ZDHHC21 expression, we
identified microRNA (miRNA) miR-30e as an important
expression regulator and found miR-30e expression to be sig-
nificantly increased within the PFC of the postmortem samples
from suicide individuals with MDD who DS.
Results
ZDHHC21 is a major 5-HT1AR palmitoyl acyltransferase.
Using a modified protocol of the acyl-biotinyl exchange (ABE)
approach14 (Supplementary Fig. 1B), we demonstrated palmi-
toylation of endogenous 5-HT1A receptors in rodent and human
brains (Fig. 1a), which was consistent with our previous finding
that recombinant 5-HT1AR is palmitoylated12. To identify the
enzyme(s) palmitoylating the 5-HT1AR, we co-transfected each
of the 23 hemagglutinin (HA)-tagged mouse ZDHHC acyl-
transferases and 5-HT1AR-CFP into neuroblastoma N1E cells
metabolically labeled with [9,10(n)3H]-palmitic acid. Sub-
stantially increased 5-HT1AR palmitoylation was observed after
co-expression of ZDHHC5, -9, and -21 (Supplementary Fig. 2A, B).
Role for these ZDHHCs was further confirmed by the ABE
approach, with ZDHHC21 as the only acyl-transferase that
significantly increased 5-HT1AR palmitoylation (Fig. 1b, c).
Notably, the candidate ZDHHCs belong to the three different
subfamilies of ZDHHC proteins with a relative low amino acid
sequence homology. Sequence homology between human
ZDHHC5 and ZDHHC9 is 43%, between ZDHHC21 and
ZDHHC9, 29%, and between ZDHHC21 and ZDHHC5, 26%.
Percentages of homology in mouse and rat are quite similar. On
the other hand, each of these ZDHHCs is highly conserved
between different mammalian species (with approximately 98%
homology between mouse, rat, and human isoforms). The three
candidate ZDHHCs show a different intracellular distribution,
with ZDHHC5 residing at the plasma membrane and ZDHHC9
and -21 localized to the Golgi15 (Supplementary Fig. 2C–E).
Noteworthy, overexpression of all relevant ZDHHCs does not
affect a preferential plasma membrane localization of the 5-
HT1AR (Supplementary Fig. 2D, E). All these ZDHHCs appeared
co-localized with 5-HT1AR. Direct evidence for interaction
between 5-HT1AR and ZDHHC5, -9, and -21 was provided in
co-immunoprecipitation experiments (Fig. 1d). In these experi-
ments, specific interaction between 5-HT1AR and relevant
ZDHHCs was analyzed by co-immunoprecipitation experiments
in N1E-115 cells co-expressing HA-tagged 5-HT1AR and green
fluorescent protein (GFP)-tagged ZDHHCs. Figure 1d shows that,
after immunoprecipitation (IP) with an antibody against the
GFP-tag, the HA-tagged receptor could be identified only in
samples derived from cells co-expressing both HA- and GFP-
tagged proteins. To determine artificial protein aggregation, cells
that expressed only one of the proteins (either HA-5-HT1AR or
GFP-tagged ZDHHC) were mixed prior to lysis and analyzed in
parallel (“mix” samples). As shown in Fig. 1d, both 5-HT1AR
and ZDHHCs can be detected by the corresponding antibody
(visible in “input” fraction), but no co-immunoprecipitation
was observed. This further verifies the specificity of 5-
HT1AR–ZDHHC interaction.
Silencing of endogenous ZDHHC5, -9, and -21 by specific
short hairpin RNAs (shRNAs, Supplementary Fig. 3A, B)
decreased palmitoylation of 5-HT1AR without influencing the
expression and distribution of 5-HT1AR in N1E cells (Fig. 1e, f;
Supplementary Fig. 3C, D). Noteworthy, knockdown of
ZDHHC9 and -21 gave the more prominent reduction of 5-
HT1AR palmitoylation in comparison to the effect mediated by
shRNA against ZDHHC5 (Fig. 1f), suggesting that both
ZDHHC9 and ZDHHC21 represent relevant palmitoyl-
acyltransferases (PATs) for 5-HT1AR. Based on the results
obtained after ZDHHC overexpression (Fig. 1b, c), we decided to
focus on ZDHHC21 as a more potent PAT for 5-HT1AR. To
determine the importance of ZDHHC21 for 5-HT1AR palmitoy-
lation in vivo, we used a ZDHHC21-deficient mouse model,
Zdhhc21dep/dep. The genetic background of this mouse includes a
spontaneous 3-bp deletion in the coding region of the Zdhhc21
gene, resulting in non-functional ZDHHC2116. In the brains of
newborn Zdhhc21dep/dep mice (P0), palmitoylation of 5-HT1AR
was significantly impaired (Fig. 1g), while global palmitoylation
profiles as well as palmitoylation of the NCAM140 protein, a
known ZDHHC3 substrate17, were not affected (Supplementary
Fig. 3F–H). It is noteworthy that, in contrast to results obtained in
newborn animals, we did not observe any decrease in palmitoyla-
tion of 5-HT1AR in the brains of adult (P30) Zdhhc21dep/dep
mice, demonstrating strong compensatory effect during develop-
ment (Supplementary Fig. 3E).
ZDHHC5, -9, and -21 regulate 5-HT1AR-mediated signaling.
We have previously demonstrated that non-palmitoylated mutant
of 5-HT1AR possesses impaired signaling properties12,13.
Therefore, we next analyzed whether knocking down the cognate
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5-HT1AR ZDHHCs would affect the receptor functions. Analysis
of 5-HT1AR-mediated cAMP changes in single N1E cells using a
fluorescence resonance energy transfer-based biosensor CEPAC18
revealed a quick and strong inhibition of forskolin-evoked cAMP
elevation upon stimulation of the wild-type 5-HT1AR. In con-
trast, expression of the palmitoylation-deficient C417/420S
mutant resulted in a significant slowdown of cAMP response
kinetics and decrease in response amplitude (Fig. 2a, c, Supple-
mentary Fig. 4A–C). A prominent attenuation of receptor-
mediated cAMP response was also observed after knocking down
of endogenous ZDHHC5, -9, or -21 in cells expressing 5-HT1AR
(Fig. 2a, c).
The 5-HT1AR is involved in activation of the mitogen-
activated protein kinase (MAPK) extracellular signal–regulated
kinase 2 (Erk2) either by a G-protein-independent pathway or via
Gβγ subunits9, while the ability of palmitoylation-deficient 5-
HT1AR to activate this pathway is substantially reduced12
(Fig. 2d, e). Analysis of Erk phosphorylation after receptor
stimulation revealed that such activation was significantly decreased
only after knocking down of ZDHHC9 and -21, suggesting that
ZDHHC5, which is localized at the plasma membrane, is not
involved in this pathway (Fig. 2d, e, Supplementary Fig. 4D, E). The
5-HT1AR (C417/420S) mutant here served as a negative control.
Silencing ZDHHC21 in cultured hippocampal neurons dimin-
ished both basal as well as 5-HT1AR agonist (i.e., 8-OH-DPAT)-
evoked GIRK currents, when compared with scramble shRNA
controls (Fig. 2f, h). These combined results demonstrate that
ZDHHC5 and -9, and in particular ZDHHC21, can regulate 5-
HT1AR-mediated signaling via modulating the receptor
palmitoylation state.
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Fig. 1 Endogenous 5-HT1AR is palmitoylated in rodent and human brains and ZDHHC21 is a major receptor palmitoyl acyltransferase. a Palmitoylation of
endogenous 5-HT1AR in human, mouse, and rat brains was assessed by the acyl-biotinyl exchange (ABE) assay (see also Supplementary Fig. 1B).
b Neuroblastoma N1E cells co-expressing 5-HT1AR and indicated ZDHHCs were analyzed by ABE (see also Supplementary Fig. 2A, B). c Quantification of
5-HT1AR palmitoylation after co-expression of ZDHHC5, -9, and -21 (n= 5). d N1E cells were co-transfected with hemagglutinin (HA)-tagged 5-HT1AR
and indicated green fluorescent protein (GFP)-tagged ZDHHCs, followed by immunoprecipitation (IP) with anti-GFP antibody and western blot with anti-
HA antibody. As a control, mixed lysates from the singly transfected cells (mix) were applied to IP. e Analysis of 5-HT1AR palmitoylation in N1E cells after
knockdown of endogenous ZDHHC5, -9, and -21 by short hairpin RNA (see also Supplementary Fig. 3A–E) together with f quantification. Western blots
shown in e are representative of at least four independent experiments. g Brain tissues isolated from the newborn (P0) F233Δ Zdhhc21dep/dep (n= 7) and
wild-type (n= 6) mice were collected for ABE analysis followed by quantification (see also Supplementary Fig. 3E–H). Bars show means ± SEM; *P <
0.05; **P < 0.01; one-way analysis of variance for c, f; two-tailed t test for g. Source data are available as a Source Data file
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Palmitoylation of 5-HT1AR in rodent depression models.
Using two different rodent models, we next investigated whether
the decreased 5-HT1AR palmitoylation can be associated with
depressive-like behavior. We first evaluated 5-HT1AR palmitoy-
lation in a paradigm of stress-induced anhedonia (decreased
reward sensitivity), serving as a well-established mouse model for
depression-like behavior19–21. After chronic application of three
stressors — social defeat stress, restraint stress, and tail suspen-
sion stress — mice exhibiting a sucrose preference of <65% were
defined as anhedonic, whereas mice that maintained a sucrose
preference of more than >65% were defined as resilient to a
depressive-like syndrome (Fig. 3a, b). Consistent with previous
work19, the immobility times in the forced swimming test were
significantly elevated in anhedonic mice versus the control and
resilient groups (Fig. 3c). Analysis of 5-HT1AR palmitoylation in
the different brain areas revealed a significant reduction in 5-
HT1AR palmitoylation but not in the expression in the PFC, a
brain area critically involved in the pathogenesis of depressive
symptoms22,23 and not in the cerebellum and hippocampus of
stress-induced anhedonic mice in comparison to the resilient
animals (Fig. 3d, e, Supplementary Fig. 5A). Importantly, the
global palmitoylation patterns and palmitoylation level of
NCAM140 in PFC, hippocampus, and cerebellum were not
affected (Supplementary Fig. 5B–E).
The decreased palmitoylation can be mediated via increased
activity of the acyl-protein thioesterases, the palmitoyl-protein
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Fig. 2 Knockdown of ZDHHC5, -9, and -21 impairs 5-HT1AR-mediated signaling. a N1E cells were transfected with cAMP fluorescence resonance energy
transfer-based biosensor CEPAC and 5-HT1AR-mCherry along with the indicated constructs (see also Supplementary Fig. 4A–C). After pretreatment with
1 µM forskolin and 25 µM 3-isobutyl-1-methylxanthine, cells were stimulated with 20 µM serotonin (5-HT). Each trace shows cAMP response at the single
cell. b Graphs show activation time constant and c changes of cAMP response amplitude relative to pretreatment (N= 4, in each experiments at least 20
cells were analyzed; one-way analysis of variance (ANOVA)). d Analysis of extracellular signal–regulated kinase (Erk) phosphorylation in N1E cells
expressing the indicated constructs after stimulation with 10 µM 5-HT. e Quantification of 5-HT evoked Erk phosphorylation calculated as the ratio of total
Erk expression over the Erk phosphorylation signal. Bars show means ± SEM (N≥ 7, one-way ANOVA; see also Supplementary Fig. 4D, E). f Representative
image of hippocampal neuron expressing short hairpin RNA against ZDHHC21 together with red fluorescent protein at the day in vitro 11. Scale bar:
100 μm. g Examples of G-protein gated inwardly rectifying potassium (GIRK) channel currents in two transfected groups after application of 5-HT1AR
agonist 8-OH-DPAT and channel blocker BaCl2. h A summary of recordings from three independent culture preparations. Bars show means ± SEM of the
amplitude of 8-OH-DPAT-stimulated GIRK currents. *P < 0.05; **P < 0.01; ***P < 0.001, two-tailed t test. Source data are available as a Source Data file
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thioesterases24, or serine hydrolases (so-called alpha-beta hydro-
lase domain or ABHD proteins) with depalmitoylating
activity25,26. Alternatively, reduced 5-HT1AR palmitoylation
could be elicited by decreased activity and/or expression of
corresponding ZDHHCs. The latter is more likely the case for 5-
HT1AR because its palmitoylation is a stable modification with a
lifetime corresponding to the lifetime of the receptor itself12.
Therefore, we investigated whether the expression level of
ZDHHC5, -9, and -21 is affected in the brain of anhedonic
mice. All three ZDHHCs are known to be ubiquitously expressed
in the brain27,28, and we found homogeneous distribution of
these ZDHHCs throughout the mouse brain with high levels of
ZDHHC9 and -21 expression in the cortex (Supplementary
Fig. 5F). Quantitative reverse transcriptase PCR (RT-PCR)
analysis revealed that the Zdhhc21 expression was significantly
attenuated only in the PFC of anhedonic mice when compared to
the resilient animals (Fig. 3f; Supplementary Fig. 5G, H).
To independently validate these results, we applied a restraint
stress-based depression model in rats29 (Fig. 4a). After 3 weeks of
being restrained for 6 h per day, animals developed a strong
depression-like phenotype characterized by increased corticoster-
one levels, lower weight gain, and increased cumulative duration
of immobility in the force swimming test (Fig. 4b, e). Similar to
results obtained in anhedonic mice, only palmitoylation and not
the expression of 5-HT1AR in the PFC, but not in the cerebellum
or hippocampus, of stressed rats was significantly decreased
without changes in global palmitoylation or in palmitoylation of
NCAM140 (Fig. 4f, g; Supplementary Fig. 6A–E). Consistent with
the finding in mouse depression model, Zdhhc21 expression level
was also reduced in the PFC of rats with depression-like behavior
(Fig. 4h). Interestingly, in the rat model for depressive-like
behavior, we found an additional decrease in the amount of
Zdhhc5 and Zdhhc9 transcripts in the PFC, while the expression
of Zdhhc5, 9 and 21 in the hippocampus and cerebellum was not
affected (Fig. 4h; Supplementary Fig. 6F, G).
Collectively, our rodent models data suggest attenuated
expression level of ZDHHC21 and reduced 5-HT1AR palmitoy-
lation as a general signature for depressive-like behavior.
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Fig. 3 Palmitoylation of 5-HT1AR and expression of ZDHHC21 are decreased in the forebrains of mice with depressive-like syndrome. a Schematic diagram
of experimental design for mouse model of depression. b Results of the sucrose preference test performed in control (n= 7) and chronically stressed mice
(n= 19). c Immobility time in the forced swim test of control and chronically stressed mice. Group of stressed mice was then divided into anhedonic
(anhed) (n= 12) and resilient (res) (n= 7) animals and immobility time was analyzed in each subgroup. One-way ANOVA. Data points represent mean ±
SEM (*P < 0.05). d In anhedonic and resilient mice, palmitoylation of the 5-HT1AR was analyzed in the prefrontal cortex (PFC) and cerebellum by acyl-
biotinyl exchange (see also Supplementary Fig. 5A–E). e Quantification of 5-HT1AR palmitoylation in anhedonic and resilient animals (see also
Supplementary Fig. 5A–E). f Relative expression levels of ZDHHC5, -9, and -21 in the PFC of resilient and anhedonic mice assessed by quantitative reverse
transcriptase-PCR. *P < 0.05; two-tailed t test. (See also Supplementary Fig. 5F–H). Source data are available as a Source Data file
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ZDHHC21 knockdown in PFC triggers depressive symptoms.
To test for a causal relationship among the level of ZDHHC21,
the degree of 5-HT1AR palmitoylation, and initiation of
depressive symptoms, we selectively knocked down the expres-
sion of this palmitoyl acyltransferase in the PFC of mice. To do
so, we generated an adenovirus-associated viral (AAV) construct
encoding the shRNAs to silence endogenously expressed
ZDHHC21 along with the red fluorescent protein under control
of the synapsin promoter, which allowed for visualization of the
infected neurons (Fig. 5a; Supplementary Fig. 7A–C, E). Bilateral
administration of this construct into the PFC of C57BL/6J mice
attenuated the expression of Zdhhc21 in the forebrain when
compared to mice treated with vehicle or scrambled shRNA
(Fig. 5b). Of note, the cortical AAV injection did not modulate
Zdhhc21 expression in the non-injected brain regions, like cere-
bellum (Supplementary Fig. 7F). Also, the expression of 5-
HT1AR in the PFC, hippocampus, and cerebellum was not
changed after AAV injection (Fig. 5c, e; Supplementary Fig. 7G).
General palmitoylation patterns as well as palmitoylation of
NCAM140, used as a control, were not affected in the mouse
brain after PFC injection of AAV encoding for the shRNA against
ZDHHC21 (Supplementary Fig. 7H, I). In contrast, 5-HT1AR
palmitoylation but not the receptor expression was selectively
reduced in the PFC (Fig 5c, e, Supplementary Fig. 7G), further
confirming ZDHHC21 as a main 5-HT1AR palmitoyl acyl-
transferase. Of importance, PFC-specific ZDHHC21 knockdown
triggered depression-like behavioral traits. In particular, the
immobility time in the forced swim test (FST) used as a readout
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for depressive-like behavior was significantly increased (Fig. 5f),
without affecting locomotor, anxiolytic, or exploratory activity as
assessed by the open field test (Fig. 5g, Supplementary Fig. 7J, K).
In addition, we did not obtain any differences between groups in
the tail suspension and the novel object recognition tests
(Supplementary Fig. 7L, M). The lack of visible effect in the tail
suspension test, which is often used for analysis of the depression-
like behavior in rodent, can be explained by the fact that the
majority of the C57BL/6J mice tested in this paradigm climbed up
their tails during the test session. Such behavior is specific for the
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C57BL/6J mouse line, which is in accordance with previous
observations30. Thus attenuated palmitoylation of the 5-HT1AR
in PFC mediated by decreased ZDHHC21 expression was suffi-
cient for the development of depressive symptoms.
5-HT1AR is a main substrate for ZDHHC21 in the mouse
PFC. To verify the substrate specificity of ZDHHC21 in the PFC
of mouse brain, we applied the quantitative palmitoylomics
approach31. In particular, we used a high-throughput ABE pro-
teomics approach that enables identification of S-Palmitoylated-
Cys sites in complex biological mixtures. Using this method in
combination with the mass spectrometry (MS) protein identifi-
cation to precisely ascertain the targets of S-palmitoylation, we
compared palmitoylation profile in the PFC of control animals
and those injected with scramble or shRNA against ZDHHC21.
Inclusion criteria used for selection of differential protein sets are
specified in detail in “Methods” section. For data evaluation, we
applied analytic approach developed for the global analysis of
proteomics data32.
Using three biological replicates, we identified 1737 palmitoy-
lated protein in the mouse PFC (Supplementary Data 1 and 2).
Detailed analysis of the palmitoylomics results revealed that
knockdown of ZDHHC21 provoked a strong (approximately
four-fold change plotted in log2 scale, which correspond to
approximately 15 times decrease in the palmitoylation level) and
highly significant (P= 0.0028) decrease of 5-HT1AR palmitoyla-
tion in comparison to the scr samples (Fig. 5h). Noteworthy that,
among three additional proteins, which palmitoylation was
reduced to the similar extent, reduction of 5-HT1AR palmitoyla-
tion was at the highest level of confidence (P= 0.0028), followed
by proteosomal ubiquitin receptor ADRM1 (P= 0.012), exopo-
lyphosphatase PRUNE1 (P= 0.017), STAT6 (P= 0.017), and
Hsc70-interacting protein (P= 0.028). For two other proteins,
including TRPC channel subfamily V (TRPV2) and phosphogly-
cerate mutase 1 (PGAM1), the level of confidence was
comparable with that of the 5-HT1AR. However, for these
proteins we obtained substantially lower decrease in palmitoyla-
tion (1.97-fold change for TRPV2 and 1.16-fold change for
PGAM1). Interestingly, with the exception of 5-HT1AR,
palmitoylation of all the above-mentioned proteins has not been
reported before. More importantly, these proteins have not been
reliably associated with MDD. Though the above-mentioned
proteins have not been associated with depression, their
palmitoylation might theoretically have an impact on the
depressive phenotype. We therefore performed additional
experiments to directly address the role of ZDHHC21-mediated
5-HT1AR palmitoylation in depression. Multiple prior studies
evidently show that the acute 8-OH-DPAT injection results in a
strong, 5-HT1AR-mediated anti-depressive effects as assessed by
decreased immobility time in the forced swimming test33,34. We
were able to reproduce this 5-HT1AR-mediated effect of 8-OH-
DPAT in control conditions, when ZDHHC21 was normally
expressed (Supplementary Fig. 7N). However, acute injection of
8-OH-DPAT failed to induce any anti-depressive effect in
animals after knockdown of ZDHHC21 in PFC (Supplementary
Fig. 7N). Together with results obtained in palmitoylomics
experiments (Fig. 5h), these combined data provide a direct
evidence for ZDHHC21-mediated 5-HT1AR palmitoylation
playing a central role in the etiology of depression-like phenotype.
ZDHHC21 expression and 5-HT1AR palmitoylation in human
brains. To validate the role of 5-HT1AR palmitoylation in MDD,
we compared levels of 5-HT1AR palmitoylation in postmortem
samples from individuals who DS and diagnosed previously with
major depression and control subjects. These groups were mat-
ched for age (mean age value in the control group was 44.2 ± 4.1
years and in the suicide group it was 42.2 ± 4.3 years), gender
(36% female in the control and 43% in the suicide group), and
race (12.5% of African American in both the groups). Although
the global palmitoylation profile as well as the palmitoylation of
defined neuronal proteins (e.g., NCAM140) was unaffected
(Supplementary Fig. 8B–D), palmitoylation of 5-HT1AR in the
PFC was significantly reduced in individuals with MDD who DS
(Fig. 6a, b). Of note, the level of 5-HT1AR expression in the PFC
of suicide subjects was unaffected (Supplementary Fig. 8A).
Furthermore, 5-HT1AR palmitoylation in other brain areas, i.e.,
those areas not central to MDD pathology, appears not to be
reduced (Fig. 6a, b).
Expression analysis in human brain samples from depressive
suicide subjects revealed that the amount of ZDHHC9 and
ZDHHC21 transcripts was significantly downregulated in the PFC
of individuals with MDD who DS, while the production of both
ZDHHCs in the cerebellum was similar to that obtained in the
control (Fig. 6c). Interestingly, in the rat model of depressive-like
behavior, we found an additional decrease in the amount of Zdhhc5
transcripts in the PFC that was not seen in the human samples from
suicide subjects (Figs. 4h and 6c), demonstrating that ZDHHC5 and
ZDHHC9 contributed differently to 5-HT1AR palmitoylation in
human and rodent brains under pathological conditions.
miRNA miR-30e regulates the ZDHHC21 expression. For a
deeper look into the molecular mechanisms regulating DHHC
activity in vivo, we focused on the possible role of miRNAs.
miRNAs are highly conserved, non-coding RNAs that regulate
gene expression of target messenger RNAs by binding to the 3’
untranslated region35. These molecules also known to regulate
expression of ZDHHC9 in neuronal populations, leading to
Fig. 5 Selective knockdown of ZDHHC21 in the prefrontal cortex (PFC) leads to development of depressive-like behavior in mice. a Cortical slice of the
C57BL/6J mouse 30 days after administration of adenovirus-associated virus encoding for short hairpin RNA (shRNA) against ZDHHC21 along with red
fluorescent protein (see also Supplementary Fig. 7A, B, E). Scale bar: 200 μm. b Relative expression levels of Zdhhc21 in the PFC after injection of the
indicated constructs (n= 4 for each group, one-way analysis of variance (ANOVA)). c PFCs of mice were isolated 30 days after injection either with
vehicle or scrambled shRNA or shRNA against ZDHHC21 and subjected to acyl-biotinyl exchange assay to define 5-HT1AR palmitoylation. Quantification
of palmitoylation (d) and expression (e) of 5-HT1AR in the PFCs of mice after injection either with vehicle or scrambled shRNA or shRNA against
ZDHHC21. f Immobility time in the forced swim test of mice treated with vehicle (n= 10), shRNA against ZDHHC21 (n= 9), or scrambled shRNA (n= 11).
Statistical significance between values is noted (*P < 0.05, **P < 0.01; one-way ANOVA; see also Supplementary Fig. 7J–M). g Comparison of the motor
activity assessed by the open field test in mice treated with vehicle, shRNA against ZDHHC21, or scrambled shRNA. h Volcano plot depicting differential S-
palmitoylation analysis between mice injected with scramble shRNA and with shRNA against ZDHHC21 using mass spectrometry spectral counts data with
estimated fold changes (x axis) versus the significance, i.e., −log10 (P values) for each protein (y axis). Dotted vertical lines lineate events with fold change
>2. Dotted horizontal lines denote point at which two-tailed t test P > 0.05. Value for 5-HT1AR is marked in red (n= 3 biological replicates for each
condition; see also Supplementary Data 1 and 2). 1, TRPC channel subfamily V (TRPV2); 2, phosphoglycerate mutase 1 (PGAM1); 3, proteosomal ubiquitin
receptor ADRM1; 4, exopolyphosphatase PRUNE1; 5, signal transducer and activator of transcription 6 (STAT6); 6, Hsc70-interacting protein. Source data
are available as a Source Data file
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changed localization of its substrate H-Ras36. In silico analysis
revealed that the 3’ untranslated region of the Zdhhc21 gene
contains conserved miRNA-binding sites for miR-338–3p, miR-
196b, miR-200a, miR-30a, and miR-30e (Supplementary Table 1).
To test the importance of these miRNAs in regulation of
ZDHHC21 expression, we mimicked a miRNA environment in
neuroblastoma cells by overexpressing the predicted miRNAs and
found that transfection of miR-200a, miR-30a, and miR-30e all
resulted in significant reductions, while transfection of miR-338-
3p showed slightly increased ZDHHC21 expression (Fig. 6d). We
then focused on miR-30a and miR-30e, i.e., the two miRNAs
showing the greatest reduction in ZDHHC21 expression, by
examining the effects on 5-HT1AR palmitoylation. In these
experiments, we found that receptor palmitoylation, but not
expression, is reduced with miR-30a and -30e overexpression
(Fig. 6e).
To directly evaluate the role of miRNA in MDD, we compared
the expression of endogenous miRNA miR-30a, -30e, and -200a in
0.0
0.2
0.4
0.6
0.8
1.0
1.2
ZDHHC5 ZDHHC9 ZDHHC21
R
el
at
iv
e 
ex
pr
es
sio
n
a
b
c
d e
f
ctrl suicide
Cerebellum
ctrl suicide
PFC
NH2OH – + – + – + – +
Scramble 30a 30e DHHC21
miRNA shRNA
0.0
0.2
0.4
0.6
0.8
1.0
1.2
ZDHHC5 ZDHHC9 ZDHHC21
R
el
at
iv
e 
ex
pr
es
sio
n
* *
Ct
rl
Su
ici
de
Ct
rl
Su
ici
de
Ct
rl
Su
ici
de
0.0
0.2
0.4
0.6
0.8
1.0
5-
H
T1
AR
 p
al
m
ito
yla
tio
n
***
Ct
rl
Su
ici
de
Ct
rl
Su
ici
de
Cerebellum
Ct
rl
Su
ici
de
Ct
rl
Su
ici
de
Ct
rl
Su
ici
de
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1
R
el
at
iv
e 
ex
pr
es
sio
n
o
f Z
dh
hc
21
30
a
19
6b
20
0a
Sc
ra
m
bl
e
30
e
33
8–
3p
miRNA
*
***
***
0.0
0.2
0.4
0.6
0.8
1.0
1.2
m
iR
-3
0a
/R
NU
48
**
Ct
rl
Su
ici
de
0.0
0.2
0.4
0.6
0.8
1.0
1.2
m
iR
-3
0e
/R
NU
48
*
0.0
0.5
1.0
1.5
2.0
2.5
m
iR
-2
00
a/
RN
U4
8
**
PFC Cerebellum
PFC
Palm 5-HT1AR
Total 5-HT1AR
Total 5-HT1AR
Palm 5-HT1AR
Ct
rl
Su
ici
de
Ct
rl
S.
Fig. 6 Attenuated 5-HT1AR palmitoylation in the prefrontal cortex (PFC) of individuals with major depressive disorder (MDD) who died by suicide
correlates with reduced expression of ZDHHC21. a 5-HT1AR palmitoylation in the PFC and cerebellum from the control and individuals with MDD who died
by suicide (PFC, n= 5; cerebellum, n= 4). b Normalized level of 5-HT1AR palmitoylation in the PFC and cerebellum of individuals with MDD who died by
suicide in comparison with control subjects (two-tailed t test; see also Supplementary Fig. 8). c Relative expression levels of ZDHHC5, -9, and -21 in the
PFC (left) and cerebellum (right) of control (n≥ 14) and individuals with MDD who died by suicide (n≥ 12). Data points represent the means ± SEM (*P <
0.05; ***P < 0.001; two-tailed t test). d N1E cells were transfected with microRNAs as indicated and the expression of ZDHHC21 was determined by
reverse transcriptase-PCR (see also Supplementary Table 1). Data points represent mean ± SEM from at least three independent experiments (*P < 0.05;
***P < 0.001; two-tailed t test). e N1E cells were transfected with 5-HT1AR along with miR-30e, miR30-a, or shRNA against ZDHHC21. Palmitoylation of 5-
HT1AR was analyzed by acyl-biotinyl exchange. Western blots shown are representative of at least three independent experiments. f Analysis of miR-30a,
-30e, and -200a expression in the PFC of control and individuals with MDD who died by suicide. (*P < 0.05, **P < 0.01; two-tailed t test). Source data are
available as a Source Data file
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the postmortem medial PFC (mPFC) samples from individuals with
MDD who DS and control subjects. These experiments revealed
that the expression of miR-30a and miR-30e was significantly
increased, while the expression of miR-200a was drastically
reduced in samples from individuals with MDD who DS
(Fig. 6f). These results provide a strong experimental support for
our hypothesis on the role of defined miRNAs in the development
of depression.
Discussion
The 5-HT1A receptor is a well-studied member of the serotonin
receptor family, in part because of its role in regulating depres-
sion- and anxiety-like behavior4. However, the precise role of 5-
HT1AR in the pathogenesis of depressive disorders and treatment
of the diseases are not fully understood. Though controversial,
several studies suggested a possible relation between depressive
disorders and abnormalities in the distribution and/or basal
expression of 5-HT1A receptor in the brain. In several studies,
decreased 5-HT1A receptor density in the PFC was reported in
positron emission tomographic and postmortem studies of MDD
patients2,37,38. In another study, however, analysis of the post-
mortem brains of depressed subjects in comparison with control
samples revealed a specific upregulation of 5-HT1A autoreceptors
in the raphe area, with no changes in postsynaptic 5-HT1AR
sites39. In contrast, other studies reported that higher 5-HT1AR
binding was correlated with increased depressive symptoms and
blunted selective serotonin reuptake inhibitor treatment
response40–42. A possible explanation for such at first glance
contradictory observations might be that compromised 5-
HT1AR-mediated signaling (e.g., through the mutations within
HTR1A gene) rather than changes in the expression level might
be responsible for MDD onset. While several rare single-
nucleotide polymorphisms (SNPs) within 5-HT1AR gene were
described, these mutations have a very low population frequency
(<2%) and failed to be associated with mental illness43–45. Apart
from changes in the expression level and gene mutations, post-
translational modifications are often a key for controlling neu-
rotransmitter receptor signaling. Lately, palmitoylation has
received increased attention46.
5-HT1AR has been shown to be palmitoylated at its C-terminal
cysteine residues Cys417 and Cys420, which is essential for
enabling Gi-protein coupling and effector-mediated signaling of
this receptor12,13. We here demonstrate that a downregulation of
5-HT1AR functions via changes of its palmitoylation status is
associated with MDD. We identified ZDHHC5, -9 and -21 as the
cognate palmitoylating enzymes and found that reduced
ZDHHC21 expression in the PFC of subjects with MDD who DS
correlates with attenuated 5-HT1AR palmitoylation status. Most
importantly, our experiments proved a causal relationship
between the PFC level of ZDHHC21, the degree of 5-HT1AR
palmitoylation, and the initiation of depressive symptoms.
It has been shown that depending on site and time of
expression defined ZDHHCs can have multiple substrates47–49. In
the present study, using a comprehensive palmitoylomics
approach we thus analyzed the substrate specificity of the more
potent PAT for 5-HT1AR, ZDHHC21. Results of our palmitoy-
lomics experiment confirmed 5-HT1AR as a main substrate for
ZDHHC21 in the PFC. Although we cannot completely exclude
an impact of other proteins, whose palmitoylation was affected
under ZDHHC21 knockdown (e.g., PRUNE1, STAT6, Hsc70-
interacting protein, TRPV2, PGAM1), these proteins have not
been reliably associated with MDD. In combination with results
obtained after acute injection of 5-HT1AR agonist 8-OH-DPAT,
which failed to evoke any anti-depressive effects in animals after
knockdown of DHHC21, this data provides a direct evidence for
ZDHHC21-mediated 5-HT1AR palmitoylation playing a central
role in the etiology of depressive phenotype.
Noteworthy, even though the substrate specificity represents a
critical component determining functional consequences of
DHHC activity, this issue was not yet systematically investigated
for the other ZDHHC members. In the majority of ZDHHC-
related studies, including identification of DHHCs responsible for
palmitoylation of phospholemman50, melanocortin receptor
MCR151, and CD3652, the question about the substrate specificity
was not addressed in detail.
Searching for mechanisms tuning ZDHHC21 expression, we
identified several miRNAs being able to modulate 5-HT1AR
palmitoylation. miRNAs are a subclass of small, noncoding,
single-stranded RNA molecules responsible for the post-
transcriptional repression or degradation of target mRNA53. Of
note, aberrant expression of specific miRNA is associated with
several psychiatric disorders, including bipolar disorder and
schizophrenia54,55. Several studies also demonstrated altered
miRNA expression profile in postmortem as well as peripheral
blood samples from MDD patients56–58. One of these studies
identified polymorphisms within the miR-30e to be positively
correlated with depression and its symptomatic onset59. MiR-30e,
an established tumor suppressor, was also found to be associated
with the development of schizophrenia60,61, although its exact
targets have not been validated. Intriguingly, our in silico search
for miRNAs that might be able to bind to the 3’ untranslated
region of the Zdhhc21 gene revealed miR-30e as a candidate for
regulation of ZDHHC21 expression. In fact, transfection of
miR-30e significantly reduced the expression of Zdhhc21 and
consequently 5-HT1AR palmitoylation, suggesting increased
expression of miR-30e as an important factor involved in initia-
tion of depressive symptoms. A strong experimental support for
our hypothesis on the role of defined miRNAs in the etiology of
MDD was provided by the fact that the expression of endogenous
miR-30a and miR-30e was significantly increased, while the
expression of miR-200a was abolished in samples from indivi-
duals with MDD who DS. It would therefore be interesting to
evaluate in future studies miR-30a, -30e, and -200a as potential
biomarkers to identify MDD patients with a suicidal mind.
Changes in miRNA expression represent an important part of
the stress response leading to MDD62,63. In search for underlying
mechanisms, an increased expression of transcription factor
REST4 in PFC was discovered in the maternally separated rat
stress model64. As REST4 is known to regulate brain-enriched
miRNAs65,66, further studies are warranted to validate whether a
stress-induced increase of REST4 expression in the PFC might
result in a local upregulation of miRNAs, including miR-30e,
which in turn represses ZDHHC21 expression.
In conclusion, our study uncovered a causal link between
regulated levels of ZDHHC21 expression, attenuated 5-HT1AR
palmitoylation, and development of depressive symptoms making
the restoration of 5-HT1AR palmitoylation (either by upregula-
tion of ZDHHC21 or inhibition of miR-30a or -30e) a possible
clinical strategy for the treatment of MDD.
Methods
Human samples. Assessment of 5-HT1AR palmitoylation in the human brains
was carried out in the PFC (Brodmann area 9) and cerebellum of individuals with
MDD who DS and 16 non-psychiatric control subjects, referred to normal controls
(NC). Brain tissues were obtained from the Maryland Brain Collection at the
Maryland Psychiatric Research Center, Baltimore. Tissues were collected only after
a family member gave informed consent. All tissue from NC and DS subjects was
examined grossly by experienced neuropathologists. Toxicology data were obtained
by the analysis of urine and blood samples. All procedures were approved by the
University of Maryland and University of Illinois institutional review boards.
Diagnosis of subjects was based on the Structured Clinical Interview for Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition (SCID I)67. At least one
family member and/or a friend, after giving written informed consent, underwent
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an interview. Diagnoses were made by a consensus of two psychiatrists from the
data obtained in this interview, medical records from the case, and records
obtained from the medical examiner’s office. Normal control subjects were verified
as free from mental illnesses using these consensus diagnostic procedures.
Animals. The behavioral experiments were with 3-month-old male C57BL/6J wild-
type mice (mouse model of stress-induced anhedonia) and 3-month-old male
Wistar rats (restraint stress model). All procedures performed on animal were
according to the guidelines of the European Communities Council Directive for the
care and use of laboratory animals and approved by the respective local govern-
mental bodies (permission 0421/000/000/2013 was issued by General Directory of
Ethical Committee of the New University of Lisbon, in accordance with Portuguese
Law-Decrees DL129/92, DL197/96 and Ordinance Port.131/97 and of the First
Warsaw Ethical Committee on animal research (permission no. 554/2013). For the
intracortical administration of AAV, adult C57BL/6J male mice (8 weeks old)
weighing about 25 ± 2 g were used. Mice were housed in the vivarium of the
Institute of Cytology and Genetics (Novosibirsk, Russia) under standard laboratory
conditions in a natural light–dark cycle (12 h light and 12 h dark) with free access
to water and food. Two days before experiments, the mice (15 animals for each of
the 3 groups) were isolated in individual cages to remove group effects. All
experimental procedures were in compliance with Guidelines for the Use of Ani-
mals in Neuroscience Research, 1992. All efforts were made to minimize the
number of animals used and their suffering. Behavioral tests were started 3 weeks
after AAV administration.
Restraint stress model in rats. Animals were housed singly in a natural
light–dark cycle (12 h light and 12 h dark). The body weight of each rat was
recorded every 7 days. Restraint stress was administered as described before29,68,69.
Briefly, rats were immobilized for 6 h each day for 3 weeks during the light phase of
the light:dark cycle. Rats were transported out of the colony room to an adjacent,
brightly lit, quiet room and were placed into restraining tubes. The restrainers were
transparent Plexiglas tubes measuring 24 cm long and 6 cm diameter with closing
flaps and air holes. Corticosterone levels in serum samples were quantified with
enzyme-linked immunosorbent assay using a commercial kit for corticosterone
(Enzo Life Sciences). Rats were tested with the FST as previously described70. All
efforts were undertaken to minimize possible suffering of animals.
Mouse model of stress-induced anhedonia. Studies were performed using 3-
month-old male C57BL/6J mice. Three-month-old male CD1 mice were used as
resident intruders for social stress, and 2–5-month-old Wistar rats were used for
predator stress. C57BL/6J mice were housed individually under a reversed 12-h
light–dark cycle (lights on: 21:00 hours) with food and water ad libitum, under
controlled laboratory conditions (22 ± 1 °C, 55% humidity). Experiments were
carried out in accordance with the European Communities Council Directive for
the care and use of laboratory animals and approved by the respective local gov-
ernmental bodies (permission 0421/000/000/2013 was issued by General Directory
of Ethical Committee of the New University of Lisbon, in accordance with Por-
tuguese Law-Decrees DL129/92 (July 6), DL197/96 (October 16), and Ordinance
Port.131/97 (November 7). All efforts were undertaken to minimize possible suf-
fering of animals.
Chronic stress procedure. We employed a 10-day stress protocol71 comprising a
dark-cycle rat exposure stress (predator stress) and light-cycle semi-random
application of two of three stressors: social defeat stress, restraint stress, and tail
suspension stress. Animals were carefully monitored for physical state and body
weight twice a day during the course of the study. Briefly, between the hours of
09:00 and 18:00 two stressors per day were employed in the following sequence:
social defeat for 30 min, restraint stress for 2 h, and tail suspension for 20 min with
an inter-session interval of at least 4 h (see below). All mice were carefully observed
after each stress session and each morning and evening and weighed. Twelve hours
after the last stressor, all mice were tested in 8-h sucrose test to assess hedonic
traits. Immediately thereafter, their forced swimming was assessed to evaluate
changes in affective behavior.
Sucrose preference test. Mice were given 8 h of free choice between two bottles of
either 1% sucrose or standard drinking water, both 3 days prior the start of the
stress study and at the end of day 10 of the stress paradigm. Other conditions of the
test were applied as described elsewhere71. Percentage preference for sucrose is
calculated using the following formula: Sucrose preference= volume (sucrose
solution)/(volume (sucrose solution)+ volume (water) × 100.
Forced swim test. The Porsolt FST has been modified to prevent behavioral
artifacts caused by stress-induced hyperlocomotion72. Floating behavior was
defined as the absence of directed movements of the animal’s head and body and
was measured by visual observation that was validated previously by automated
scoring with the CleverSys software (CleverSys, VA, US).
Open field test. Open field test for mice was performed as previously described73.
Stereotactic injection in the PFC of mice and 8-OH-DPAT treatment. AAVs at
the final concentration of 109 viral genomes per one µl were administered intra-
cortically using TSE stereotaxic instrument (TSE Systems, Germany) according to
the following coordinates: AP: +1.5mm, L: +1.0mm, DV: 2mm and AP: +1.5 mm,
L: +1.0 mm, DV: 2 mm. Prior operation, mice were anesthetized with 400 µl of
2.5% solution of the 2,2,2-tribromethanol (Sigma-Aldrich, T48402) and 2-methyl-
2-butanol (Sigma-Aldrich, A1685) mixture (1:1). The volume of intracortically
administered liquid was 2.0 µl in each hemisphere. Mice of control groups received
2.0 µl of pure vehicle or scrambled shRNA-based AAVs in each hemisphere. In
several experiment, FST was performed in control animals or in mice injected with
the AAVs after acute treatment with 5-HT1AR agonist 8-OH-DPAT (1 mg/kg,
intraperitoneally) or saline performed 20 min before the test.
Cell culturing and transfection. Mouse neuroblastoma clone N1E-115 (N1E cells)
(ATCC® Number: CRL-2263TM) were grown in the complete Dulbecco’s modified
Eagle’s medium (DMEM; Invitrogen) supplemented with 10% fetal bovine serum
(Gibco) and 1% penicillin/streptomycin (Gibco) at 37 °C and 5% CO2. The cells
were transfected using LipofectamineTM2000 Reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer’s protocol. Primary hippocampal neuronal cultures
were prepared as previously described74 and transfected using Lipofectami-
neTM2000 according to the manufacturer’s manual.
List of antibodies. The following antibodies were used: 5-HT1AR (1:200 western
blot (WB), 1:200 immunocytochemistry (ICC), 1 µg/ml IP; Alomone Labs (ASR-
021), 5HT1A receptor (1:200 WB; Abcam ab64994), p44/42 MAPK (Erk1/2)
(1:1000 WB; Cell Signaling Technology 9102), phospho-p44/42 MAPK (Erk1/2)
(Thr202/Tyr204) (1:1000 WB; Cell Signaling Technology 9101), GFP (1 µg/ml for
IP; GeneTex GTX26556), GFP (Horseradish peroxidase (HRP)) 1:1000 WB;
GeneTex LS-C50850–500), HA probe (Y-11) Santa Cruz sc-805 (2 µg IP), synap-
tophysin 1 (1:50 ICC; Synaptic Systems 101 002), biotin (HRP; 1:500 WB; Sigma
A4541), TGN38 (1:100 ICC; Thermo Scientific MA3–063), HA-peroxidase, high
affinity (3F10) (1:8000 WB; Roche 12 013 819 001), Alexa Fluor® 647 mouse anti-
GM130 (1:100 ICC; BD Biosciences 558712), ZDHHC9 polyclonal antibody (1:200
WB; Thermo Fisher Scientific PA5–26721), ZDHHC21 polyclonal antibody (1:200
WB; Thermo Fisher Scientific), and DHHC5 antibody (1:200 WB; ProSci Incor-
porated 54–211). NCAM antibodies75 were kind gifts from Dr. Martina
Muehlenhoff.
DNA constructs, AAV vectors, and intracortical administration. The 23 DHHC
proteins were a kind gift from Masaki Fukata76. Plasmids encoding for shRNA for
specific knockdown of different Zdhhcs were designed by Oligoengene (Seattle,
WA, USA). Double-stranded oligonucleotides containing a target sequence were
inserted into the pSUPER.neo+GFP vector for scrambling into the pSUPERIOR.
retro.neo+gfp. The target sequences for selected shRNA constructs were as follows:
Scrambled—5’-GCGCGCTTTGTAGGATTCG-3’; DHHC5—5’-
ACCTCCACCTCCTATAAGA-3’; DHHC9—5’-GAGGAAAGTGGAAGTCGAC-
3’; NS DHHC21—5’-CAAGATCCCACATGCAGAG-3’. To generate knockdown
of the Zdhhc21 gene in vivo in mouse brains, mouse-specific shRNA 5’-CAA-
GATCCCACATGCAGAG-3’ was subcloned into the pAAV-Syn(0.5)-EGFP-H1-2
vector14 at BglII and SalI restriction sites. Similarly, scrambled shRNA 5’-
ACTACCGTTGTTATAGGTG-3’ was subcloned to be used as a control. The
resulted plasmids were co-transfected with DJ vector and pHelper (Cell Biolabs Inc,
USA) in HEK293-FT cells (ATCC) using Lipofectamine-3000 (Thermo Fisher
Scientific Inc.). AAVs were collected after 48 h and then used for local intracortical
infection of C57BL/6J mice in vivo. AAVs were administered intracortically using
TSE stereotaxic instrument (TSE Systems, Germany) according to the following
coordinates: AP, 1.5 mm and L, −1.0 mm; DV, 1 mm and AP, 1.5 mm; L, +1.0 mm
and DV, 1 mm77. The volume of intracortically administered liquid was 2.5 µl in
each hemisphere. Mice of control groups received 2.5 µl of pure vehicle or
scrambled shRNA-based AAVs in each hemisphere. To confirm AAV infection,
acute brain slices were subjected to microscopic analysis. Before analysis, animals
were perfused with paraformaldehyde solution.
Metabolic labeling and IP. N1E cells were co-transfected with 5-HT1AR-CFP and
plasmids encoding for individual DHHC-HA enzymes. Twenty-four hours after
transfection, cells were labeled in serum-free DMEM containing [3H] palmitic acid
(300 µCi/ml, 30–60 Ci/mmol) (American Radiolabeled Chemicals Inc.) for 2 h at
37 °C and 5% CO2. Cells were lysed in RIPA buffer (pH 7.4), and 5-HT1AR was
immunoprecipitated. Receptor was eluted, and samples were subjected to sodium
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and autoradiography.
Erk1/2 phosphorylation assay. Twenty-four hours after transfection, N1E cells
were stimulated with 10 µM serotonin (5-HT) (Sigma) for 5 min. Cells were lysed
in ice-cold lysis buffer containing 150 mM NaCl, 50 mM Tris/Cl, 0.5% sodium
deoxycholate, 1% Triton X-100, 0.1% SDS, 1 mM sodium orthovanadate, 50 mM
NaF, and 10 mM di-monosodium phosphate (pH 7.5) with freshly added PIs and
1 mM PMSF. Immunoblots were analyzed using p44/42 MAPK (Erk1/2) and
phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) antibodies.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11876-5 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:3924 | https://doi.org/10.1038/s41467-019-11876-5 | www.nature.com/naturecommunications 11
Analysis of protein palmitoylation by ABE assay. To analyze palmitoylated
proteins in recombinant system as well as in native tissue, the ABE assay (Sup-
plementary Fig. 1) was prepared as previously described14.
Analysis of cAMP response. N1E cells expressing the mCerulean-Epac-Citrine
(CEPAC) biosensor18, 5-HT1AR-mCherry, and shRNAs against individual
ZDHHCs tagged with GFP were used for live cell imaging with the Zeiss LSM780.
After 2 min of acquisition, cells were pre-stimulated with 1 µM forskolin (Sigma)
and 25 µM 3-isobutyl-1-methylxanthine (Sigma) to increase intracellular cAMP to
sub-saturation levels. After 6 min, when cAMP reached a constant level, 5-HT1AR
was stimulated with 20 µM 5-HT (Sigma), and the change in acceptor/donor
fluorescence intensity ratio of CEPAC was obtained in online fingerprinting mode
and further processed as previously described78.
Analysis of the intracellular distribution of 5-HT1AR and ZDHHCs. N1E-115
cells were co-transfected with the GFP-tagged ZDHHC and 5-HT1AR-mCherry.
Sixteen hours after transfection, cells were imaged using LSM780. Offline analysis
of fluorescence intensity distribution was carried out using the Fiji software. To
quantify fluorescence intestines of GFP and mCherry at the Golgi compartment
and at the plasma membrane, two ROIs (regions of interest) corresponding to these
organelles were drawn. The median intensity of each channel for each ROI was
quantified and the ratio of membrane versus Golgi intensity was calculated sepa-
rately for each protein.
Patch-clamp recordings from hippocampal neurons. On day in vitro 8, primary
hippocampal neurons were transfected with either a control pSUPER.neo+GFP/
scrambled shRNA plasmid (1 µg per well) or with shRNA against ZDHHC21 (1 µg
per well, pSUPER expression vector) to silence the expression of endogenously
expressed ZDHHC21. Neurons were used for electrophysiological recordings
3–4 days after the transfection. Whole-cell recordings from pyramidal neurons
were obtained using electrodes with a resistance of 3–4MOhm. The electrodes
were filled with a solution comprising the following components (in mM): 130 K-
gluconate, 8 NaCl, 4 Mg-ATP, 0.3 Na-GTP, 0.5 EGTA, 10 HEPES, pH 7.25. Cells
were placed in HEPES-buffered saline with the following composition (in mM):
119 NaCl, 5 KCl, 2 CaCl2, 2 MgCl2, 25 HEPES, 20 D-glucose, 0.0005 Na+ channel
blocker tetrodotoxin citrate (Tocris), 0.001 5-HT7R antagonist SB-269970 (Tocris),
pH 7.3. Currents were recorded with an EPC 10 USB Patch Clamp Amplifier
(HEKA Elektronik). Data acquisition was controlled using the PATCHMASTER
software (HEKA Elektronik). The mean amplitudes of currents of three indepen-
dent experiments activated 180–200 ms after the beginning of the voltage step were
measured and statistically evaluated using Student’s t test.
Palmitoylomics. Proteins purified from ABE approach were dissolved in 2% SDS
Buffer, diluted with 19 volumes of 50mM TRIS, 100mM NaCl, and 1mM EDTA,
and digested in solution with trypsin (GOLD TRYPSIN for MS) by incubating at
37 °C for 60min. The resulting peptide mixtures were applied to RP-18 pre-column
(Waters, Milford, MA) using water containing 0.1% formic acid (FA) as a mobile
phase and then transferred to a nano-high-performance liquid chromatography (LC)
RP-18 column (internal diameter 75 µM, Waters, Milford, MA) using acetonitrile
(ACN) gradient (0–35% ACN in 160min) in the presence of 0.1% FA at a flow rate
of 250 nl/min. The column outlet was coupled directly to the ion source of Q-
exactive Orbitrap mass spectrometer (Thermo Electron Corp., San Jose, CA) working
in the regime of data-dependent MS to MS/MS switch. A blank run ensuring absence
of cross-contamination from previous samples preceded each analysis.
All MS data sets were searched against SwissProt protein database (Swissprot
2018_02; 16,905 sequences) using the MASCOT search engine (MatrixScience,
London, UK, Mascot Server 2.5.1). Both the peptide and fragment mass tolerance
settings were established separately for individual LC-MS/MS runs after a
measured mass recalibration, as described previously79. After recalibration, the mass
tolerance for proteins was in the range 5–10 ppm and for peptides 0.01–0.05 Da.
The Mascot search parameters were as follows: enzyme, Trypsin; missed cleavages,
1; variable modifications N-Ethylmaleimide (C), carbamidomethyl (C), Oxidation
(M); instrument, HCD; Decoy option, active. False discovery rate (FDR) was
estimated with Mascot Decoy search and score threshold was adjusted for each
sample to keep the FDR <1%. Probable contaminants (e.g., keratins and albumin)
were removed from the identified protein/peptide lists.
The MS data have been deposited to the ProteomeXchange Consortium via the
PRIDE partner repository (http://www.ebi.ac.uk/pride/archive/) with the data set
identifier PXD012736. For evaluation of the relative protein abundance in each
sample, spectral count values determined using emPAI scores were used as
previously described31,80. For data sets generated by the protein-based procedure,
spectral counts were merged over all biological replicates. Subsequently, statistical
analysis was performed on the merged data sets. For the protein data set, missing
values were imputed; all zeros were replaced with 1. Only proteins that met the
acceptance criteria: FDR < 1%, at least two unique peptides, Mascot score >25, non-
redundant proteins, were taken for further analysis. The protein-wise natural
logarithms (ln) of specific ratios were calculated. Significance were computed (P
values) using variance t test. Proteins with P values <0.05 were accepted as S-
palmitoylated candidates (Supplementary Data 1 and 2). The statistical significance
of the difference between control/scramble/shDHHC21 (enriched, reduced, no
influence) was calculated using the unequal variance two-tailed heteroscedastic t
test. It was assumed that log2 shDHHC21/scramble and/or log2 shDHHC21/
control and or scramble/control <−2.0 (5% threshold) and −1.0 (105 threshold)
reflected reduction when >1.0 and 2.0 reflected induction of palmitoylation of the
given protein. Then statistical significance of the difference between spectral counts
for each protein was estimated with the unequal variance one-tailed,
heteroscedastic t test. It was assumed that a palmitoylated protein was identified
with high confidence, when the P value of the difference between two biological
conditions was ≤0.05 or ≤0.001 (Supplementary Data 2). All palmitoylomics raw
data are deposited at the PRIDE repository (PXD012736).
Quantitative real-time PCR analysis. Total RNA was isolated using RNeasy® Plus
Mini Kit (QIAGEN) according to the manufacturer’s protocol. RNA was reverse
transcribed into cDNA using SuperScript® III First-Strand Synthesis System
(Invitrogen), and the expression analysis was performed using TaqMan® Gene
Expression Assay (Applied Biosystems). For the detection of Zdhhc5, Zdhhc9, and
Zdhhc21, the gene-specific primers were Mm00523158_m1, Mm00552609_m1,
Mm00509795_m1, Rn01747138_m1, Rn01462327_m1, and Rn01764799_m1
(Applied Biosystems), respectively. The following primers were used for detection
of ZDHHC in human samples: ZDHHC5, Hs00379814_m1; ZDHHC9,
Hs00211318_m1; and ZDHHC21, Hs00944036_m1. The relative gene expression
was calculated using the ΔΔCT method.
miRNA analysis. To establish the importance of the predicted miRNAs (see
Supplementary Table 1) in regulating the Zdhhc21 expression, we mimicked a
miRNA environment in N1E cells by overexpressing the miRNAs of interest. N1E
cells were transfected with specific pre-miR™ miRNA Precursor Molecules
(Ambion, Applied Biosystems) by a liposomal-based method (Lipofectamine™2000,
Invitrogen) according to the manufacturer’s instructions. After 72 h, cells were
washed and RNA was isolated and subjected to RT-PCR analysis.
For analysis of miRNA expression in human postmortem samples, total RNA
from the mPFC was isolated using the miRNeasy Mini Kit (Qiagen) according to
the manufacturer’s instructions. Quantification of RNA was performed with
Synergy HT Reader (BioTek). Single miRNA expression analysis was validated
using TaqMan MiRNA assays (Applied Biosystems) for miR-30a, miR-30e, and
miR-200a in a two-step approach. Real-time PCR was performed on a QuantStudio
system (Applied Biosystems). For internal normalization of miRNA expression
levels, housekeeping RNA RNU48 was chosen, and relative quantification was
performed using internal dilution series for each single target.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the corresponding
authors upon reasonable request. Palmitoylomics raw data are stored on the PRIDE
repository http://www.ebi.ac.uk/pride/archive/projects/PXD012736 (PXD012736). The
source data underlying Figs. 1, 2, 3, 4, 5, 6 are available as a Source Data file.
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